

Abbie Adams

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8830355/publications.pdf>

Version: 2024-02-01

13
papers

608
citations

932766

10
h-index

1125271

13
g-index

13
all docs

13
docs citations

13
times ranked

635
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted SMN Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies. <i>Biomedicines</i> , 2021, 9, 552.	1.4	6
2	Phenotypeâ€“genotype correlations in a pseudodominant Stargardt disease pedigree due to a novel <i>ABCA4</i> deletionâ€“insertion variant causing a splicing defect. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1259.	0.6	12
3	A Morpholino Oligomer Therapy Regime That Restores Mitochondrial Function and Prevents mdx Cardiomyopathy. <i>JACC Basic To Translational Science</i> , 2018, 3, 391-402.	1.9	5
4	Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies. <i>PLoS ONE</i> , 2016, 11, e0145620.	1.1	17
5	Antisense Oligonucleotide Induction of Progerin in Human Myogenic Cells. <i>PLoS ONE</i> , 2014, 9, e98306.	1.1	10
6	Impaired functional communication between the L-type calcium channel and mitochondria contributes to metabolic inhibition in the <i>mdx</i> heart. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2905-14.	3.3	42
7	Multiple exon skipping strategies to by-pass dystrophin mutations. <i>Neuromuscular Disorders</i> , 2012, 22, 297-305.	0.3	17
8	Dystrophin Isoform Induction In Vivo by Antisense-mediated Alternative Splicing. <i>Molecular Therapy</i> , 2010, 18, 1218-1223.	3.7	23
9	Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping. <i>Molecular Therapy</i> , 2009, 17, 1418-1426.	3.7	43
10	The Influence of Antisense Oligonucleotide Length on Dystrophin Exon Skipping. <i>Molecular Therapy</i> , 2007, 15, 157-166.	3.7	74
11	Antisense Oligonucleotide-induced Exon Skipping Across the Human Dystrophin Gene Transcript. <i>Molecular Therapy</i> , 2007, 15, 1288-1296.	3.7	146
12	Morpholino Oligomerâ€“Mediated Exon Skipping Averts the Onset of Dystrophic Pathology in the mdx Mouse. <i>Molecular Therapy</i> , 2007, 15, 1587-1592.	3.7	150
13	Induced dystrophin exon skipping in human muscle explants. <i>Neuromuscular Disorders</i> , 2006, 16, 583-590.	0.3	63